Agenus, a Lexington, MA-based immuno-oncology firm creating new therapeutics for high-unmet want cancers, obtained an funding from Zynext Ventures.
The quantity of the deal was not disclosed.
Led by CEO Dr. Garo Armen, Agenus develops a lead program comprising Botensilimab (BOT) and Balstilimab (BAL), which is a brand new immunotherapy platform designed to strengthen and maintain the immune system’s response towards tumour cells. Presently in superior medical trials, BOT/BAL have demonstrated important medical exercise throughout 9 most cancers sorts in additional than 1,200 sufferers, together with each late-stage and neoadjuvant settings.
The corporate intends to make use of the funds to broaden operations and R&D efforts to speed up growth of its lead BOT/BAL program and strategically broaden into high-unmet want indications and earlier strains of therapy.
FinSMEs
03/06/2025
